|
|
xiii | |
About the editors |
|
xvii | |
Preface to the seventh edition |
|
xxi | |
Preface to the sixth edition |
|
xxiii | |
Preface to the fifth edition |
|
xxv | |
Preface to the fourth edition |
|
xxvii | |
Preface to the third edition |
|
xxix | |
Preface to the second edition |
|
xxxi | |
Preface to the first edition |
|
xxxiii | |
Introduction: Historic perspective (1955--2015) |
|
xxxv | |
|
1 Molecular and genomic methodologies for clinicians |
|
|
1 | (6) |
|
|
|
Clinical molecular and genomic methodologies: goals |
|
|
1 | (1) |
|
Methods of genetic analysis |
|
|
1 | (3) |
|
Interpretation of genetic variants obtained from next-generation sequencing |
|
|
4 | (1) |
|
Applications of next-generation sequencing to oncology |
|
|
4 | (2) |
|
Interpreting and evaluating the results from clinical genetic testing |
|
|
6 | (1) |
|
Further reading and references |
|
|
6 | (1) |
|
2 Hematologic manifestations of systemic illness |
|
|
7 | (30) |
|
|
|
Alterations to red blood cells related to organ-specific pathologies |
|
|
7 | (5) |
|
Alterations to white blood cells related to organ-specific pathologies |
|
|
12 | (1) |
|
Alterations to platelets and coagulation related to organ-specific pathologies |
|
|
13 | (2) |
|
General considerations for the hematologic sequelae of infection |
|
|
15 | (1) |
|
Viral and bacterial illnesses associated with marked hematologic sequelae |
|
|
15 | (6) |
|
Parasitic illnesses associated with marked hematologic sequelae |
|
|
21 | (1) |
|
Hemolytic uremic syndrome |
|
|
22 | (1) |
|
|
23 | (2) |
|
|
25 | (2) |
|
Nutritional deficiencies and environmental exposures |
|
|
27 | (1) |
|
Marrow infiltrative disorders |
|
|
28 | (6) |
|
Further reading and references |
|
|
34 | (3) |
|
3 Classification and diagnosis of anemia in children and neonates |
|
|
37 | (24) |
|
|
|
Classification and diagnosis |
|
|
37 | (3) |
|
|
40 | (19) |
|
Further reading and references |
|
|
59 | (2) |
|
|
61 | (20) |
|
|
|
61 | (1) |
|
|
61 | (10) |
|
|
71 | (9) |
|
Further reading and references |
|
|
80 | (1) |
|
5 Lymphadenopathy and diseases of the spleen |
|
|
81 | (10) |
|
|
|
81 | (5) |
|
|
86 | (3) |
|
Further reading and references |
|
|
89 | (2) |
|
|
91 | (34) |
|
|
|
|
|
91 | (11) |
|
Inherited bone marrow failure syndromes |
|
|
102 | (20) |
|
Further reading and references |
|
|
122 | (3) |
|
7 General considerations of hemolytic diseases, red cell membrane, and enzyme defects |
|
|
125 | (26) |
|
|
|
Clinical features of hemolytic disease |
|
|
125 | (1) |
|
|
126 | (2) |
|
|
128 | (10) |
|
Paroxysmal nocturnal hemoglobinuria |
|
|
138 | (4) |
|
|
142 | (6) |
|
Further reading and references |
|
|
148 | (3) |
|
8 Extracorpuscular hemolytic anemia |
|
|
151 | (10) |
|
|
|
|
151 | (7) |
|
Nonimmune hemolytic anemia |
|
|
158 | (1) |
|
Further reading and references |
|
|
159 | (2) |
|
|
161 | (32) |
|
|
|
|
161 | (18) |
|
Sickle cell trait (heterozygous form, AS) |
|
|
179 | (1) |
|
|
179 | (1) |
|
|
180 | (1) |
|
|
180 | (1) |
|
|
180 | (11) |
|
Further reading and references |
|
|
191 | (2) |
|
10 Primary and secondary erythrocytosis |
|
|
193 | (14) |
|
|
|
Erythrocytosis or polycythemia |
|
|
193 | (2) |
|
|
195 | (2) |
|
|
197 | (6) |
|
Diagnostic approach to erythrocytosis |
|
|
203 | (1) |
|
Further reading and references |
|
|
204 | (3) |
|
11 Disorders of white blood cells |
|
|
207 | (30) |
|
|
|
|
207 | (1) |
|
|
208 | (1) |
|
|
208 | (9) |
|
|
217 | (3) |
|
|
220 | (6) |
|
|
226 | (2) |
|
|
228 | (7) |
|
|
235 | (1) |
|
Further reading and references |
|
|
235 | (2) |
|
12 Disorders of platelets |
|
|
237 | (50) |
|
|
|
Thrombocytopenia in the newborn |
|
|
237 | (11) |
|
Inherited thrombocytopenias |
|
|
248 | (9) |
|
Immune thrombocytopenic purpura |
|
|
257 | (8) |
|
Other causes of thrombocytopenia |
|
|
265 | (5) |
|
|
270 | (2) |
|
Qualitative platelet disorders |
|
|
272 | (8) |
|
Inherited vascular and connective tissue disorders |
|
|
280 | (1) |
|
Nonthrombocytopenic purpura |
|
|
281 | (1) |
|
Laboratory evaluation of platelets and platelet function |
|
|
282 | (2) |
|
Further reading and references |
|
|
284 | (3) |
|
13 Disorders of coagulation |
|
|
287 | (54) |
|
|
|
|
287 | (10) |
|
Acquired coagulation factor disorders |
|
|
297 | (2) |
|
Inherited coagulation factor disorders |
|
|
299 | (16) |
|
|
315 | (17) |
|
|
332 | (7) |
|
Further reading and references |
|
|
339 | (2) |
|
|
341 | (16) |
|
|
|
|
|
341 | (1) |
|
|
341 | (2) |
|
Simple vascular malformations |
|
|
343 | (1) |
|
Diagnostic work-up for vascular lesions |
|
|
344 | (3) |
|
|
347 | (1) |
|
Evaluation and monitoring of a vascular hepatic tumor |
|
|
348 | (2) |
|
Vascular anomaly syndromes |
|
|
350 | (6) |
|
Further reading and references |
|
|
356 | (1) |
|
|
357 | (20) |
|
|
|
|
357 | (1) |
|
Langerhans cell histiocytosis |
|
|
357 | (12) |
|
Other histiocytic disorders |
|
|
369 | (2) |
|
Hemophagocytic lymphohistiocytosis (hemophagocytic syndromes) |
|
|
371 | (3) |
|
Further reading and references |
|
|
374 | (3) |
|
16 Lymphoproliferative disorders |
|
|
377 | (14) |
|
|
Angioimmunoblastic lymphadenopathy with dysproteinemia |
|
|
377 | (1) |
|
Small lymphocytic infiltrates of the orbit and conjunctiva (ocular adnexal lymphoid proliferation, pseudolymphoma, benign lymphoma, atypical lymphocytic infiltrates) |
|
|
378 | (1) |
|
Angiocentric immunolymphoproliferative disorders |
|
|
378 | (1) |
|
Castleman disease (angiofollicular lymph node hyperplasia, benign giant lymph node hyperplasia, angiomatous lymphoid hamartoma) |
|
|
379 | (1) |
|
Epstein---Barr virus-associated Lymphoproliferative disorders in immunocompromised individuals |
|
|
380 | (5) |
|
X-linked lymphoproliferative syndrome |
|
|
385 | (1) |
|
Autoimmune lymphoproliferative syndrome |
|
|
386 | (3) |
|
Lymphomatoid papulosis in children |
|
|
389 | (1) |
|
Further reading and references |
|
|
390 | (1) |
|
17 Myelodysplastic syndromes and myeloproliferative disorders |
|
|
391 | (22) |
|
|
|
|
Myelodysplastic syndromes |
|
|
391 | (7) |
|
Myeloid proliferations in children with Down syndrome (DS) |
|
|
398 | (1) |
|
Juvenile myelomonocytic leukemia |
|
|
398 | (5) |
|
Myeloproliferative neoplasms |
|
|
403 | (6) |
|
Further reading and references |
|
|
409 | (4) |
|
18 Acute lymphoblastic leukemia |
|
|
413 | (26) |
|
|
|
|
413 | (1) |
|
|
413 | (1) |
|
|
414 | (2) |
|
|
416 | (1) |
|
|
417 | (3) |
|
Cytogenetics and molecular genetics of ALL |
|
|
420 | (1) |
|
|
421 | (1) |
|
|
422 | (7) |
|
|
429 | (1) |
|
Philadelphia-positive ALL |
|
|
430 | (1) |
|
|
431 | (1) |
|
|
431 | (1) |
|
Relapse in children with ALL |
|
|
431 | (2) |
|
|
433 | (1) |
|
Central nervous system relapse |
|
|
434 | (2) |
|
Long-term effects of ALL therapy |
|
|
436 | (1) |
|
Future drugs in ALL therapy |
|
|
436 | (1) |
|
Further reading and references |
|
|
437 | (2) |
|
19 Acute myeloid leukemia |
|
|
439 | (20) |
|
|
|
Incidence and epidemiology |
|
|
439 | (1) |
|
Etiology and predisposing conditions |
|
|
439 | (1) |
|
|
440 | (1) |
|
Diagnostic and monitoring studies |
|
|
441 | (1) |
|
|
442 | (5) |
|
|
447 | (1) |
|
The treatment of newly diagnosed AML |
|
|
448 | (2) |
|
Prognosis of newly diagnosed AML |
|
|
450 | (1) |
|
Relapsed and refractory AML |
|
|
450 | (1) |
|
Novel therapeutic approaches |
|
|
451 | (3) |
|
Acute promyelocytic leukemia |
|
|
454 | (2) |
|
|
456 | (1) |
|
Further reading and references |
|
|
457 | (2) |
|
|
459 | (14) |
|
|
|
Etiology and epidemiology |
|
|
459 | (1) |
|
|
459 | (1) |
|
|
460 | (1) |
|
|
460 | (1) |
|
|
461 | (3) |
|
Diagnostic evaluation and staging |
|
|
464 | (1) |
|
|
465 | (1) |
|
|
466 | (5) |
|
|
471 | (1) |
|
Further reading and references |
|
|
471 | (1) |
|
|
472 | (1) |
|
|
473 | (12) |
|
|
|
|
473 | (1) |
|
Incidence and epidemiology |
|
|
473 | (1) |
|
Pathologic classification |
|
|
474 | (1) |
|
|
475 | (1) |
|
|
475 | (1) |
|
|
476 | (1) |
|
|
476 | (1) |
|
|
477 | (2) |
|
Non-Hodgkin Lymphoma Subtypes |
|
|
479 | (3) |
|
Further reading and references |
|
|
482 | (3) |
|
22 Central nervous system tumors |
|
|
485 | (22) |
|
|
|
|
485 | (1) |
|
|
486 | (2) |
|
|
488 | (2) |
|
|
490 | (2) |
|
|
492 | (11) |
|
Genetic syndromes related to brain tumors |
|
|
503 | (1) |
|
Further reading and references |
|
|
504 | (3) |
|
|
507 | (18) |
|
|
|
|
|
507 | (1) |
|
|
507 | (1) |
|
|
507 | (1) |
|
|
508 | (2) |
|
|
510 | (1) |
|
|
511 | (2) |
|
Prognosis, risk stratification, and therapy |
|
|
513 | (9) |
|
Neuroblastoma in the adolescent and young adult |
|
|
522 | (1) |
|
Further reading and references |
|
|
522 | (3) |
|
|
525 | (16) |
|
|
|
|
525 | (13) |
|
|
538 | (1) |
|
Congenital mesoblastic nephroma |
|
|
538 | (1) |
|
Clear cell sarcoma of the kidney |
|
|
539 | (1) |
|
Rhabdoid tumor of the kidney |
|
|
539 | (1) |
|
|
539 | (1) |
|
Further reading and references |
|
|
540 | (1) |
|
25 Rhabdomyosarcoma and other soft-tissue sarcomas |
|
|
541 | (22) |
|
|
|
Incidence and epidemiology |
|
|
541 | (1) |
|
Pathologic and genetic classification |
|
|
542 | (3) |
|
|
545 | (2) |
|
|
547 | (2) |
|
|
549 | (2) |
|
|
551 | (1) |
|
|
552 | (6) |
|
Follow-up after completion of therapy |
|
|
558 | (1) |
|
|
559 | (1) |
|
|
560 | (1) |
|
Further reading and references |
|
|
561 | (2) |
|
|
563 | (20) |
|
|
|
|
563 | (9) |
|
Ewing sarcoma family of tumors |
|
|
572 | (6) |
|
|
578 | (3) |
|
Further reading and references |
|
|
581 | (2) |
|
|
583 | (14) |
|
|
|
|
583 | (1) |
|
|
583 | (2) |
|
Risk for second malignant neoplasms |
|
|
585 | (1) |
|
|
586 | (1) |
|
|
586 | (1) |
|
|
587 | (1) |
|
|
587 | (1) |
|
|
588 | (1) |
|
|
588 | (1) |
|
|
589 | (1) |
|
Treatment of intraocular RB |
|
|
590 | (4) |
|
Treatment of recurrent RB |
|
|
594 | (1) |
|
Treatment of extraocular RB |
|
|
594 | (1) |
|
|
594 | (1) |
|
Further reading and references |
|
|
595 | (2) |
|
28 Extracranial germ cell tumors |
|
|
597 | (16) |
|
|
|
|
597 | (1) |
|
|
597 | (1) |
|
|
597 | (1) |
|
Molecular characteristics |
|
|
598 | (1) |
|
|
599 | (1) |
|
|
600 | (1) |
|
Staging and risk stratification |
|
|
601 | (1) |
|
|
601 | (6) |
|
Risk-stratified therapeutic approaches |
|
|
607 | (3) |
|
Relapsed and resistant germ cell tumors |
|
|
610 | (1) |
|
Further reading and references |
|
|
610 | (3) |
|
|
613 | (10) |
|
|
|
|
613 | (1) |
|
|
613 | (2) |
|
|
615 | (1) |
|
|
615 | (1) |
|
|
615 | (2) |
|
Staging and risk stratification |
|
|
617 | (1) |
|
|
618 | (2) |
|
Further reading and references |
|
|
620 | (3) |
|
30 Hematopoietic stem cell transplantation and cellular therapy |
|
|
623 | (36) |
|
|
|
Allogeneic stem cell transplantation |
|
|
623 | (5) |
|
HSC sources, collection, and manipulation |
|
|
628 | (2) |
|
Graft manipulation postcollection |
|
|
630 | (1) |
|
Medical evaluation of HSC donors |
|
|
630 | (1) |
|
Pretransplantation preparative regimens (conditioning) |
|
|
631 | (4) |
|
|
635 | (1) |
|
|
636 | (16) |
|
|
652 | (3) |
|
|
655 | (2) |
|
Further reading and references |
|
|
657 | (2) |
|
31 Management of oncologic emergencies |
|
|
659 | (16) |
|
|
|
|
|
659 | (4) |
|
Cardiothoracic emergencies |
|
|
663 | (1) |
|
|
664 | (2) |
|
|
666 | (2) |
|
|
668 | (1) |
|
|
669 | (2) |
|
Treatment-associated emergencies |
|
|
671 | (2) |
|
Further reading and references |
|
|
673 | (2) |
|
32 Supportive care of patients with cancer |
|
|
675 | (38) |
|
|
|
Management of infectious complications |
|
|
675 | (11) |
|
Recognition and management of nausea and vomiting |
|
|
686 | (2) |
|
|
688 | (2) |
|
|
690 | (6) |
|
Nutritional status of the oncology patient |
|
|
696 | (2) |
|
Utilization of hematopoietic growth factors |
|
|
698 | (2) |
|
Management of acute radiation side effects |
|
|
700 | (3) |
|
|
703 | (5) |
|
Posttreatment immunizations |
|
|
708 | (1) |
|
|
709 | (1) |
|
Further reading and references |
|
|
710 | (3) |
|
33 Evaluation, investigations, and management of late effects of childhood cancer |
|
|
713 | (22) |
|
|
|
Models of survivorship care |
|
|
713 | (1) |
|
Interventions and screening guidelines |
|
|
714 | (2) |
|
Organ system---specific late effects |
|
|
716 | (17) |
|
|
733 | (1) |
|
Further reading and references |
|
|
733 | (2) |
|
34 Psychosocial factors impacting children with cancer and their families |
|
|
735 | (14) |
|
|
|
735 | (5) |
|
|
740 | (2) |
|
|
742 | (1) |
|
During relapses and recurrences |
|
|
743 | (1) |
|
Treatment outcomes: the unsuccessful course |
|
|
744 | (2) |
|
Treatment outcomes: the successful course |
|
|
746 | (1) |
|
|
747 | (1) |
|
Further reading and references |
|
|
748 | (1) |
|
35 Pediatric blood banking principles and transfusion medicine practices |
|
|
749 | (18) |
|
|
|
|
749 | (1) |
|
|
749 | (1) |
|
Donor recruitment and testing |
|
|
750 | (1) |
|
Blood collection and processing |
|
|
751 | (2) |
|
|
753 | (3) |
|
Blood component modification and administration |
|
|
756 | (2) |
|
|
758 | (3) |
|
|
761 | (2) |
|
|
763 | (1) |
|
|
764 | (1) |
|
Further reading and references |
|
|
765 | (2) |
Appendix 1 Hematological reference values |
|
767 | (14) |
Index |
|
781 | |